Understanding the Behavior of Amorphous Pharmaceutical Systems during Dissolution
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
To investigate the underlying physical processes taking place during dissolution of amorphous pharmaceuticals and correlate them to the observed solution concentration-time profiles. Felodipine and indomethacin were used as model hydrophobic compounds.
Concentration-time profiles were monitored during dissolution of the model amorphous compounds using in situ fiber-optic ultraviolet spectroscopy. Crystallization of the solid exposed to an aqueous environment was monitored using Raman spectroscopy and/or powder X-ray diffraction. Polarized light microscopy was used to provide qualitative information about crystallization processes.
For felodipine, a small extent of supersaturation was generated via dissolution at 25°C but not at 37°C. The amorphous solid was found to crystallize rapidly at both temperatures upon exposure to the dissolution medium. Addition of low concentrations of polymers to the dissolution medium was found to delay crystallization of the amorphous solid, leading to the generation of supersaturated solutions. Amorphous indomethacin did not crystallize as readily in an aqueous environment; hence, dissolution resulted in supersaturated solutions. However, crystallization from these supersaturated solutions was rapid. Polymeric additives were able to retard crystallization from supersaturated solutions of both indomethacin and felodipine for up to 4 h.
The dissolution advantage of amorphous solids can be negated either by crystallization of the amorphous solid on contact with the dissolution medium or through rapid crystallization of the supersaturated solution. Polymeric additives can potentially retard both of these crystallization routes, leading to the generation of supersaturated solutions that can persist for biologically relevant timeframes.
- Leuner C, Dressman J. Improving drug solubility for oral delivery using solid dispersions. Eur J Pharm Biopharm. 2000;50:47–60. CrossRef
- Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Delivery Rev. 1997;23:3–25. CrossRef
- Ambike AA, Mahadik KR, Paradkar A. Spray-dried amorphous solid dispersions of simvastatin, a low Tg drug: in vitro and in vivo evaluations. Pharm Res. 2005;22:990–8. CrossRef
- Six K, Verreck G, Peeters J, Brewster M, Van den Mooter G. Increased physical stability and improved dissolution properties of itraconazole, a class II drug, by solid dispersions that combine fast- and slow-dissolving polymers. J Pharm Sci. 2004;93:124–31. CrossRef
- Yamashita K, Nakate T, Okimoto K, Ohike A, Tokunaga Y, Ibuki R, et al. Establishment of new preparation method for solid dispersion formulation of tacrolimus. Int J Pharm. 2003;267:79–91. CrossRef
- Kennedy M, Hu J, Gao P, Li L, Ali-Reynolds A, Chal B, et al. Enhanced bioavailability of a poorly soluble vr1 antagonist using an amorphous solid dispersion approach: a case study. Mol Pharm. 2008;5:981–93. CrossRef
- Kim MS, Jin SJ, Kim JS, Park HJ, Song HS, Neubert RHH, et al. Preparation, characterization and in vivo evaluation of amorphous atorvastatin calcium nanoparticles using supercritical antisolvent (SAS) process. Eur J Pharm Biopharm. 2008;69:454–65. CrossRef
- Law D, Schmitt EA, Marsh KC, Everitt EA, Wang WL, Fort JJ, et al. Ritonavir-PEG 8000 amorphous solid dispersions: in vitro and in vivo evaluations. J Pharm Sci. 2004;93:563–70. CrossRef
- Vaughn JM, McConville JT, Crisp MT, Johnston KP, Williams RO. Supersaturation produces high bioavailability of amorphous danazol particles formed by evaporative precipitation into aqueous solution and spray freezing into liquid technologies. Drug Dev Ind Pharm. 2006;32:559–67. CrossRef
- Marsac PJ, Konno H, Taylor LS. A comparison of the physical stability of amorphous felodipine and nifedipine systems. Pharm Res. 2006;23:2306–16. CrossRef
- Shamblin SL, Tang XL, Chang LQ, Hancock BC, Pikal MJ. Characterization of the time scales of molecular motion in pharmaceutically important glasses. J Phys Chem B. 1999;103:4113–21. CrossRef
- Wu T, Yu L. Surface crystallization of indomethacin below T-g. Pharm Res. 2006;23:2350–5. CrossRef
- Yu L. Amorphous pharmaceutical solids: preparation, characterization and stabilization. Adv Drug Delivery Rev. 2001;48:27–42. CrossRef
- Zhou D, Zhang GGZ, Law D, Grant DJW, Schmitt EA. Thermodynamics, molecular mobility and crystallization kinetics of amorphous griseofulvin. Mol Pharm. 2008;5:927–36. CrossRef
- Hancock BC, Parks M. What is the true solubility advantage for amorphous pharmaceuticals? Pharm Res. 2000;17:397–404. CrossRef
- Chikaraishi Y, Otsuka M, Matsuda Y. Dissolution phenomenon of the piretanide amorphous form involving phase change. Chem Pharm Bull. 1996;44:2111–5.
- Fukuoka E, Makita M, Yamamura S. Glassy state of pharmaceuticals. 2. Bioinequivalence of glassy and crystalline indomethacin. Chem Pharm Bull. 1987;35:2943–8.
- Savolainen M, Kogermann K, Heinz A, Aaltonen J, Peltonen L, Strachan C, et al. Better understanding of dissolution behaviour of amorphous drugs by in situ solid-state analysis using Raman spectroscopy. Eur J Pharm Biopharm. 2009;71:71–9. CrossRef
- Windbergs M, Jurna M, Offerhaus HL, Herek JL, Kleinebudde P, Strachan CJ. Chemical imaging of oral solid dosage forms and changes upon dissolution using coherent anti-stokes Raman scattering microscopy. Anal Chem. 2009;81:2085–91. CrossRef
- Konno H, Taylor LS. Influence of different polymers on the crystallization tendency of molecularly dispersed amorphous felodipine. J Pharm Sci. 2006;95:2692–705. CrossRef
- Matsumoto T, Zografi G. Physical properties of solid molecular dispersions of indomethacin with poly(vinylpyrrolidone) and poly(vinylpyrrolidone-co-vinylacetate) in relation to indomethacin crystallization. Pharm Res. 1999;16:1722–8. CrossRef
- Van den Mooter G, Wuyts M, Blaton N, Busson R, Grobet P, Augustijns P, et al. Physical stabilisation of amorphous ketoconazole in solid dispersions with polyvinylpyrrolidone K25. Eur J Pharm Sci. 2001;12:261–9. CrossRef
- Weuts I, Kempen D, Decorte A, Verreck G, Peeters J, Brewster M, et al. Physical stability of the amorphous state of loperamide and two fragment molecules in solid dispersions with the polymers PVP-K30 and PVP-VA64. Eur J Pharm Sci. 2005;25:313–20. CrossRef
- Hoffman JD. Thermodynamic driving force in nucleation and growth processes. J Chem Phys. 1958;29:1192–3. CrossRef
- Konno H, Handa T, Alonzo DE, Taylor LS. Effect of polymer type on the dissolution profile of amorphous solid dispersions containing felodipine. Eur J Pharm Biopharm. 2008;70:493–9. CrossRef
- Taylor LS, Zografi G. Spectroscopic characterization of interactions between PVP and indomethacin in amorphous molecular dispersions. Pharm Res. 1997;14:1691–8. CrossRef
- Towler CS, Taylor LS. Spectroscopic characterization of intermolecular interactions in solution and their influence on crystallization outcome. Cryst Growth Des. 2007;7:633–8. CrossRef
- Marsac PJ, Konno H, Rumondor ACF, Taylor LS. Recrystallization of nifedipine and felodipine from amorphous molecular level solid dispersions containing poly(vinylpyrrolidone) and sorbed water. Pharm Res. 2008;25:647–56. CrossRef
- Sato T, Okada A, Sekiguchi K, Tsuda Y. Difference in physico-pharmaceutical properties between crystalline and noncrystalline 9, 3″-diacetylmidecamycin. Chem Pharm Bull. 1981;29:2675–82.
- Zhu L, Wong L, Yu L. Surface-enhanced crystallization of amorphous nifedipine. Mol Pharm. 2008;5:921–6. CrossRef
- Ishida H, Wu TA, Yu LA. Sudden rise of crystal growth rate of nifedipine near T-g without and with polyvinylpyrrolidone. J Pharm Sci. 2007;96:1131–8. CrossRef
- Wu T, Sun Y, Li N, de Villiers MM, Yu L. Inhibiting surface crystallization of amorphous indomethacin by nanocoating. Langmuir. 2007;23:5148–53. CrossRef
- Andronis V, Yoshioka M, Zografi G. Effects of sorbed water on the crystallization of indomethacin from the amorphous state. J Pharm Sci. 1997;86:346–51. CrossRef
- Bhugra C, Pikal MJ. Role of thermodynamic, molecular, and kinetic factors in crystallization from the amorphous state. J Pharm Sci. 2008;97:1329–49. CrossRef
- Lachman L, Lieberman HA, Kanig JL. The theory and practice of industrial pharmacy. Stipes Publishing LLC, 1986.
- Mullin JW. Crystallization. 4th ed. Oxford: Elsevier Butterworth-Heinemann; 2001.
- Garside J, Mersmann A, Nyvlt J. Measurement of Crystal Growth and Nucleation Rates. 2nd ed. Rugby: Institute of Chemical Engineers; 2002.
- Understanding the Behavior of Amorphous Pharmaceutical Systems during Dissolution
Volume 27, Issue 4 , pp 608-618
- Cover Date
- Print ISSN
- Online ISSN
- Springer US
- Additional Links
- Industry Sectors
- Author Affiliations
- 1. Department of Industrial and Physical Pharmacy, School of Pharmacy, Purdue University, 575 Stadium Mall Drive, West Lafayette, Indiana, 47907, USA
- 2. Global Pharmaceutical R&D, Abbott Laboratories, 100 Abbott Park Road, Abbott Park, Illinois, 60064, USA
- 3. Global Pharmaceutical Operation, Abbott Laboratories, 100 Park Road, Abbott, Illinois, 60064, USA